You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Novartis’ oral therapy iptacopan shows promise in PNH

Novartis has revealed new positive data for its investigational treatment iptacopan as a monotherapy treatment for patients with the rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH).